FIELD: medical equipment.
SUBSTANCE: system for controlled pulmonary delivery of a pharmacologically active agent comprises an inhalation device for pulmonary delivery to a subject of a evaporated amount of a pharmacologically active agent, contained in vegetal material, due to controlled heating of said plant material, in order to evaporate said evaporated amount of said agent. One or both of the user interface and sensor, each of which is configured to obtain data, indicate a pharmacodynamic effect induced by said agent in a subject. Sensor is configured to monitor the pharmacodynamic effect, and the user interface is configured to analyze the input data of the subject when the subject interacts with the user interface to assess the pharmacodynamic effect based on the interaction analysis. Controller is connected to the inhalation device and is configured to control the evaporated amount based on the data, received from one or both of user interface and sensor.
EFFECT: technical result is reduced delivery of herbal medicine.
22 cl, 5 tbl, 21 dwg
Title | Year | Author | Number |
---|---|---|---|
METHOD AND DEVICE FOR EVAPORATION AND INHALATION OF RELEASED SUBSTANCES | 2015 |
|
RU2690401C2 |
METHOD AND APPARATUS FOR EVAPORATION AND INHALATION OF ISOLATED SUBSTANCES | 2020 |
|
RU2752613C1 |
METHOD AND DEVICE FOR EVAPORATION AND INHALATION OF RELEASED SUBSTANCES | 2019 |
|
RU2733642C2 |
TREATMENT OF HEART FAILURE IN HUMANS | 2020 |
|
RU2811365C2 |
LEVODOPA FORMULATIONS FOR RAPID RELIEF OF PARKINSON'S DISEASE | 2013 |
|
RU2685718C2 |
METHOD FOR PREVENTING GLP-1 SIDE EFFECTS | 2008 |
|
RU2474415C2 |
ACTIVE SUBSTANCE DELIVERY | 2008 |
|
RU2467741C2 |
COMBINATION THERAPY FOR TREATMENT OF PULMONARY HYPERTENSION | 2017 |
|
RU2763525C2 |
REDUCTION OF INPATIENT VARIABILITY OF LEVODOPA CONCENTRATIONS IN BLOOD PLASMA | 2013 |
|
RU2682681C2 |
AEROSOLIZED FLUOROQUINOLONES AND USES THEREOF | 2006 |
|
RU2603638C2 |
Authors
Dates
2020-07-30—Published
2015-06-30—Filed